Welcome to our dedicated page for Ingersoll Rand news (Ticker: $IR), a resource for investors and traders seeking the latest updates and insights on Ingersoll Rand stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ingersoll Rand's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ingersoll Rand's position in the market.
Ingersoll Rand has led a $19M financing round for Inkbit, a pioneer in advanced additive manufacturing solutions. The funding will advance Inkbit's Vision-Controlled Jetting™ (VCJ) technology, enabling rapid manufacturing of innovative products like complex industrial fluidics and bio-inspired robots. Inkbit's technology reimagines the traditional assembly line, combining scalability, reliability, and intelligence to build multi-functional products in one pass.
Ingersoll Rand reported record first quarter revenues, Adjusted EBITDA, and Adjusted EPS. The company raised its total company Adjusted EBITDA and Adjusted EPS guidance for 2024, showcasing a strong performance driven by Ingersoll Rand Execution Excellence (IRX). Despite a decline in orders, the two-year stack shows an improvement, with reported revenues and net income also on the rise. The company maintains a healthy liquidity of $3.5 billion and has raised its 2024 guidance for Adjusted EBITDA and Adjusted EPS. Ingersoll Rand is focused on delivering long-term value to shareholders through strategic acquisitions and comprehensive capital allocation strategies.
Ultima Genomics, a developer of an innovative ultra-high throughput sequencing architecture, announced the addition of Mark Stevenson, a seasoned executive with over 30 years of experience in the life sciences sector, to its Board of Directors. Stevenson, the former Executive Vice President and COO of Thermo Fisher Scientific, brings valuable expertise in next-generation sequencing technologies and innovation. His appointment is expected to bolster Ultima Genomics' position in the genomics and healthcare fields.
